TY - JOUR
T1 - Statin use improves survival in patients with pancreatic ductal adenocarcinoma
T2 - A meta-analysis
AU - Tamburrino, Domenico
AU - Crippa, Stefano
AU - Partelli, Stefano
AU - Archibugi, Livia
AU - Arcidiacono, Paolo Giorgio
AU - Falconi, Massimo
AU - Capurso, Gabriele
N1 - Publisher Copyright:
© 2020 Editrice Gastroenterologica Italiana S.r.l.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Background: Previous studies on statins’ effect on survival of patients with pancreatic ductal adenocarcinoma (PDAC) report conflicting results. Aims: To evaluate the association between statin use and PDAC patients’ survival. Methods: A systematic review and meta-analysis was performed including case-control, cohort studies and randomized controlled trials assessing the association between statin use and survival in PDAC patients. Pooled HRs with 95%CIs were calculated using random effects model; publication bias was assessed through Begg and Mazumdar test and heterogeneity by I2 value. Results: 14 studies with 33,137 PDAC patients, 40% under statins, were included. Statins use was associated to a reduced death risk (HR 0.871; 95%CI: 0.819; 0.927; p = 0.0001) suggesting a protective effect, homogeneous for different geographic areas. This effect was significant in surgically resected patients (HR 0.50; 95%CI: 0.32; 0.76; p = 0.001) but not in those with advanced disease (HR 0.78; 95%CI: 0.59; 1.02; p = 0.07). In studies providing information on statin type, only rosuvastatin resulted associated to a reduced risk of death (HR 0.88; 95%CI: 0.81; 0.96; p = 0.004). Conclusions: Statins use is significantly associated with a reduced risk of death in resected PDAC patients. This finding has to be considered with caution due to publication bias and the availability of only few studies for sensitivity analyses.
AB - Background: Previous studies on statins’ effect on survival of patients with pancreatic ductal adenocarcinoma (PDAC) report conflicting results. Aims: To evaluate the association between statin use and PDAC patients’ survival. Methods: A systematic review and meta-analysis was performed including case-control, cohort studies and randomized controlled trials assessing the association between statin use and survival in PDAC patients. Pooled HRs with 95%CIs were calculated using random effects model; publication bias was assessed through Begg and Mazumdar test and heterogeneity by I2 value. Results: 14 studies with 33,137 PDAC patients, 40% under statins, were included. Statins use was associated to a reduced death risk (HR 0.871; 95%CI: 0.819; 0.927; p = 0.0001) suggesting a protective effect, homogeneous for different geographic areas. This effect was significant in surgically resected patients (HR 0.50; 95%CI: 0.32; 0.76; p = 0.001) but not in those with advanced disease (HR 0.78; 95%CI: 0.59; 1.02; p = 0.07). In studies providing information on statin type, only rosuvastatin resulted associated to a reduced risk of death (HR 0.88; 95%CI: 0.81; 0.96; p = 0.004). Conclusions: Statins use is significantly associated with a reduced risk of death in resected PDAC patients. This finding has to be considered with caution due to publication bias and the availability of only few studies for sensitivity analyses.
KW - Meta-analysis
KW - Pancreatic cancer
KW - PDAC
KW - Statin
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85080078334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080078334&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2020.01.008
DO - 10.1016/j.dld.2020.01.008
M3 - Review article
C2 - 32113888
AN - SCOPUS:85080078334
VL - 52
SP - 392
EP - 399
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 4
ER -